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To the Editor: Despite improved
public health, serious infections with
nontyphoidal  Salmonella enterica
remain a major clinical and public
health concern in Thailand and
worldwide (1,2). Life-threatening
Salmonella infections resistant to flu-
oroquinolones, extended-spectrum
cephalosporins, or both, have been
increasingly reported (3). Use of
antimicrobial drugs for disease pre-
vention and growth promotion in
food animals has been implicated in
this increase in drug resistance (4).
Because of extensive global travel,
such increases affect the medical
community domestically and interna-
tionally (5). We report a pilot survey
of drug resistance in Salmonella spp.
in Thailand.
We studied archival nontyphoidal
Salmonella isolates from bacteremic
patients at King Chulalongkorn
Memorial Hospital from January 2003
to October 2005 and from bacteremic
patients in Thailand sent to the World
Health Organization National
Salmonella and  Shigella Center in
Bangkok during the first half of 2005.
The isolates from these archives were
nonoverlapping and were kept frozen
at −80°C. Isolates were divided into
Salmonella serovar Choleraesuis and
other nontyphoidal Salmonella (non-
Choleraesuis) because we observed
that Choleraesuis isolates show a high-
er frequency of resistance to fluoro-
quinolones and extended-spectrum
cephalosporins than non-Choleraesuis
isolates. A standard Etest method (AB
Biodisk, Solna, Sweden) was used to
evaluate MICs for nalidixic acid,
ciprofloxacin, and ceftriaxone.
Susceptibility was defined according
to the 2005 criteria for Salmonella of
the Clinical Laboratory Standards
Institute (CLSI, formerly NCCLS) (6).
Isolates showed high frequencies
of antimicrobial drug resistance
(Figure). All S. Choleraesuis isolates
with ceftriaxone resistance also
showed high levels of resistance to
nalidixic acid (MIC >256  µg/mL);
most of these also had reduced sus-
ceptibility to ciprofloxacin (MIC
>0.125  µg/mL). Of 73 nalidixic
acid–resistant Salmonella isolates, 55
(75%) required a ciprofloxacin MIC
>0.125 µg/mL, 14 (19%) required an
MIC of 0.094 µg/mL, and 4 (6%)
required an MIC of 0.064 µg/mL. One
patient with aortitis caused by ceftri-
axone-resistant  S. Choleraesuis died
of a ruptured mycotic aneurysm.
In the food animal industry, the
effect of using antimicrobial drugs has
long been a subject of concern (7–9).
Evidence from molecular epidemio-
logic studies (9) suggests that these
concerns are genuine and that serious
problems must be addressed. This
concern is also supported by reports
of fatal, invasive, nontyphoidal
Salmonella infections resistant to
quinolones or extended-spectrum
cephalosporins (7,10). In Thailand,
enrofloxacin, a veterinary fluoro-
quinolone, is used in animals in the
poultry, swine, and seafood industries.
Ceftiofur, a third-generation cephalo-
sporin, is used extensively in swine
for treatment and prevention of dis-
ease and for growth promotion. When
compared with previous susceptibility
patterns (5), current nontyphoidal
Salmonella infections in humans in
Thailand are more resistant to
quinolones and cephalosporins.
Susceptibility to nalidixic acid corre-
lates well with reduced susceptibility
to ciprofloxacin. An alarming increase
in ceftriaxone resistance in S.
Choleraesuis may be associated with
inappropriate cephalosporin use in
swine farming. Major revisions in
current policies for use of antimicro-
bial drugs in food animals in Thailand
are warranted.
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Figure. Percentage of nontyphoidal Salmonella isolates resistant to nalidixic acid (NA) and
ceftriaxone (CTRX), Thailand. KCMH, King Chulalongkorn Memorial Hospital; WHO-
Salm, World Health Organization Salmonella and Shigella Center. Cho, Choleraesuis;
non-Cho, non-Choleraesuis. The analysis included 10 Cho isolates from KCMH, 44 Cho
isolates from WHO-Salm, 27 non-Cho isolates from KCMH, and 41 non-Cho isolates from
WHO-Salm. Two Cho isolates from WHO-Salm with intermediate MICs for ceftriaxone are
also included.LETTERS
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Fulminant
Supraglottitis from
Neisseria 
meningitidis
To the Editor: A 68-year-old
Caucasian woman with non–insulin-
dependent diabetes mellitus, hyper-
tension, and peripheral vascular dis-
ease sought treatment at an emer-
gency department after experiencing
2 days of pharyngitis and 1 day of
fatigue and dysphagia for solid food.
The morning of admission she noted
dysphagia for solid food and liquids,
dysphonia, severe anterior neck pain,
neck swelling and erythema, dyspnea,
and a temperature of 102.3°F (39°C).
A computed tomographic (CT) scan
demonstrated substantial neck soft tis-
sue edema and narrowing of the
oropharynx and hypopharynx. She
received single doses of intravenous
ampicillin/sulbactam, clindamycin,
dexamethasone (10 mg), and methyl-
prednisolone (125 mg) before being
evacuated by air to our intensive care
unit (ICU) at Walter Reed Army
Medical Center. Intravenous ampi-
cillin/sulbactam, 3 g every 6 hours,
and clindamycin, 900 mg every 8
hours, were continued after the trans-
fer. Two doses of intravenous van-
comycin, 1 g every 12 hours, were
given before vancomycin was discon-
tinued. Results of laboratory studies
were the following: leukocyte count
13.3/mm3 (71% polymorphonuclear
leukocytes, 18% bands) and normal
hematocrit, platelet count, blood urea
nitrogen and creatinine concentra-
tions, and liver-associated enzymes.
A marker pen was used to track
the rapid advance of erythema
overnight from her anterior, inferior
chin to the top of her breasts (Figure).
The infectious disease service was
consulted the next morning. When she
was examined, her condition had
improved; she had normal vital signs,
a slightly hoarse voice, and the ability
to swallow some saliva. She had no
headache or meningismus. The chest
erythema was receding. Oral exami-
nation demonstrated erythema and an
abrasion in the posterior pharynx. Her
tongue was not elevated and her uvula
was midline. Anterior firm edema
without crepitus extended from her
chin to the mid-neck. Results of her
examination were otherwise unre-
markable. The infectious disease con-
sultant recommended restarting a
course of vancomycin and discontinu-
ing clindamycin.
A follow-up CT scan with con-
trast demonstrated anterior cervical
soft tissue edema and patent airway
with surrounding abnormal thickness
and soft tissue density. No abscess or
clot was seen. Endoscopic examina-
tion in the ICU showed diffuse erythe-
ma and generalized supraglottic
edema affecting mostly the epiglottis
and arytenoids. Dental examination
demonstrated no acute pathologic fea-
tures. Blood cultures at our hospital
yielded no growth, and throat culture
was negative for group Astreptococci.
The patient recovered without
requiring intubation (Figure). On the
day of discharge, a blood culture from
the referring hospital’s emergency
department was reported to be posi-
tive for Neisseria meningitidis,
serogroup Y. Immediate family mem-
bers and the otolaryngologists who
conducted the endoscopic examina-
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